SINGAPORE (Oct 28): DBS Group Research is maintaining its “buy” call Japfa with higher $1.18 target, encouraging investors to take advantage of the attractive valuations offered by the Indonesia-based supplier of animal protein.

(See also: Japfa’s 3Q earnings surge to US$48 mil on higher sales and margins)

In a Friday research note, analyst Ben Santoso says Japfa’s EBITDA is projected to expand by 16% to US$464.8 million ($648 million) next year from nearly US$400 million, driven by continued growth in all segments.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook